Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Antibody-Drug-Conjugate (ADC) company reports patient death

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 10, 2023 8:21pm

146 Views

Post# 35582959

RE:RE:RE:RE:RE:RE:Antibody-Drug-Conjugate (ADC) company reports patient death

In 2020, Seagen entered into global co-development and co-commercialization agreement with Merck for Ladiratuzumab Vedotin (LV) in breast cancer and other solid tumors. Seagen received $600 million upfront and is eligible for progress-dependent milestone payments up to $2.6 billion.

Additionally, Merck made a $1 billion equity investment in Seagen. With Merck stepping away from a Seagen acquisition, Seagen recently discontinued development in Ladiratuzumab Vedotin.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market